A UK Real-world Evaluation of Efficacy and Toxicity of Second-line Trastuzumab Emtansine and Third-line Trastuzumab Deruxtecan in HER2-positive Advanced Breast Cancer

Purpose: Trastuzumab emtansine is routinely offered to patients in the second-line setting for advanced human epidermal growth factor receptor 2 (HER-2)-positive breast cancers. There is a paucity of UK real-world data on the progression-free survival (PFS) with trastuzumab emtansine therapy after prior pertuzumab and the risk of cardiotoxicity. Trastuzumab deruxtecan is currently approved for use after 2 or more anti-HER2 therapies based on DESTINY-Breast01 single-arm trial showing an overall response rate of 60.9% and median PFS of 16.4 [1].

Source: Clinical Oncology - May 6, 2023 Category: Radiology Authors: S. Peters, H.C. Tang, T. Shafiq, S. Karim, S. Khan, S. Trivedi, A. Anand, H.B. Sheikh, S. Saghir, J. Lui, D.S. Prabhu, T. Mathew, E.A. Rakha, S. Madhusudan Source Type: research